AstraZeneca lung cancer immunotherapy trial fails, dealing blow to company

Data from the Phase III MYSTIC study showed Imfinzi and tremelimumab did not extend survival in first-line NSCLC. AstraZeneca’s shares were down on the news.

Article Source: AstraZeneca lung cancer immunotherapy trial fails, dealing blow to company.